Erythropoietin Drugs

Erythropoietin Drugs

Global Erythropoietin Drugs Market to Reach $13.4 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Erythropoietin Drugs estimated at US$10 Billion in the year 2020, is projected to reach a revised size of US$13.4 Billion by 2027, growing at a CAGR of 4.3% over the analysis period 2020-2027. Epoetin-Alfa, one of the segments analyzed in the report, is projected to record a 4.5% CAGR and reach US$7.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Darbepoetin-Alfa segment is readjusted to a revised 4.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $2.9 Billion, While China is Forecast to Grow at 4% CAGR

The Erythropoietin Drugs market in the U.S. is estimated at US$2.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2027 trailing a CAGR of 4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.2% and 3.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.Epoetin-Beta Segment to Record 3.5% CAGR

In the global Epoetin-Beta segment, USA, Canada, Japan, China and Europe will drive the 3.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$907.4 Million in the year 2020 will reach a projected size of US$1.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 12 Featured) -

  • Amgen, Inc.
  • Biocon Ltd.
  • Celltrion, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Hospira, Inc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • LG Life Sciences India Pvt., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Erythropoietin Drugs – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 2: World Historic Review for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 3: World 15-Year Perspective for Erythropoietin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
TABLE 4: World Recent Past, Current & Future Analysis for Epoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 5: World Historic Review for Epoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 6: World 15-Year Perspective for Epoetin-alfa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 7: World Recent Past, Current & Future Analysis for Epoetin-beta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 8: World Historic Review for Epoetin-beta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 9: World 15-Year Perspective for Epoetin-beta by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 10: World Recent Past, Current & Future Analysis for Darbepoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 11: World Historic Review for Darbepoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 12: World 15-Year Perspective for Darbepoetin-alfa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 13: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 14: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 15: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 16: World Recent Past, Current & Future Analysis for Kidney Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 17: World Historic Review for Kidney Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 18: World 15-Year Perspective for Kidney Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 21: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 22: World Erythropoietin Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027
TABLE 23: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 24: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 25: World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 26: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 27: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 28: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 30: USA Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 31: USA 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2012, 2021 & 2027
TABLE 32: USA Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 33: USA Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 34: USA 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2012, 2021 & 2027
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 36: Canada Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 37: Canada 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2012, 2021 & 2027
TABLE 38: Canada Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 39: Canada Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 40: Canada 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2012, 2021 & 2027
JAPAN
Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 42: Japan Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 43: Japan 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2012, 2021 & 2027
TABLE 44: Japan Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 45: Japan Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 46: Japan 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2012, 2021 & 2027
CHINA
Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 48: China Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 49: China 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2012, 2021 & 2027
TABLE 50: China Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 51: China Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 52: China 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2012, 2021 & 2027
EUROPE
Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 54: Europe Historic Review for Erythropoietin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 55: Europe 15-Year Perspective for Erythropoietin Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
TABLE 56: Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 57: Europe Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 58: Europe 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2012, 2021 & 2027
TABLE 59: Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 60: Europe Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 61: Europe 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2012, 2021 & 2027
FRANCE
Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 63: France Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 64: France 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2012, 2021 & 2027
TABLE 65: France Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 66: France Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 67: France 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2012, 2021 & 2027
GERMANY
Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 69: Germany Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 70: Germany 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2012, 2021 & 2027
TABLE 71: Germany Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 72: Germany Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 73: Germany 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2012, 2021 & 2027
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 75: Italy Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 76: Italy 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2012, 2021 & 2027
TABLE 77: Italy Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 78: Italy Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 79: Italy 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2012, 2021 & 2027
UNITED KINGDOM
Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 81: UK Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 82: UK 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2012, 2021 & 2027
TABLE 83: UK Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 84: UK Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 85: UK 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2012, 2021 & 2027
REST OF EUROPE
TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 87: Rest of Europe Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 88: Rest of Europe 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2012, 2021 & 2027
TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 90: Rest of Europe Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 91: Rest of Europe 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 93: Asia-Pacific Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 94: Asia-Pacific 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2012, 2021 & 2027
TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 96: Asia-Pacific Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 97: Asia-Pacific 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2012, 2021 & 2027
REST OF WORLD
TABLE 98: Rest of World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 99: Rest of World Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 100: Rest of World 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2012, 2021 & 2027
TABLE 101: Rest of World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 102: Rest of World Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 103: Rest of World 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2012, 2021 & 2027
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings